PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
7545698-4	1995	Both prednisolone and GH alleviated the hypoglycemia, concomitantly with increases in IGF-I, IGFBP-3, and ALS levels.	Prednisolone	5-17	insulin like growth factor 1	Homo sapiens	86-91	
23038624-0	2013	Prednisolone reduces the ability of serum to activate the IGF1 receptor in vitro without affecting circulating total or free IGF1.	Prednisolone	0-12	insulin like growth factor 1	Homo sapiens	58-62	
23038624-5	2013	RESULTS: Prednisolone treatment reduced IGF1 bioactivity by 12.6% from 2.22+-0.18 to 1.94+-0.15 mug/l (P=0.01) compared with placebo.	Prednisolone	9-21	insulin like growth factor 1	Homo sapiens	40-44	
11509866-4	2001	RESULTS: IGF-I levels increased by 99% during GH administration and 67% during co-administration of GH and prednisolone (p < 0.0005), whereas no significant change was seen during prednisolone alone.	Prednisolone	107-119	insulin like growth factor 1	Homo sapiens	9-14	
16079165-10	2006	Serum IGF1 was increased in patients with v without prednisolone, indicating IGF1 resistance (mean (SEM): 221 (23) v 122 (14) microg/l, p<0.001).	Prednisolone	52-64	insulin like growth factor 1	Homo sapiens	6-10	
16079165-11	2006	Adalimumab treatment decreased the raised IGF1 levels in patients with prednisolone, so that after 12 weeks of treatment they reached the level of patients without prednisolone.	Prednisolone	71-83	insulin like growth factor 1	Homo sapiens	42-46	
11922563-0	2002	Low free and total insulinlike growth factor I (IGF-I) and IGF binding protein-3 levels in chronic inflammatory bowel disease: partial normalization during prednisolone treatment.	Prednisolone	156-168	insulin like growth factor 1	Homo sapiens	19-46	
11922563-0	2002	Low free and total insulinlike growth factor I (IGF-I) and IGF binding protein-3 levels in chronic inflammatory bowel disease: partial normalization during prednisolone treatment.	Prednisolone	156-168	insulin like growth factor 1	Homo sapiens	48-53	
11922563-10	2002	CONCLUSIONS: Marked changes in serum total and free IGF-I and IGFBPs were demonstrated in patients with severe exacerbation of CIBD without complete normalization during high dose prednisolone treatment and tapering.	Prednisolone	180-192	insulin like growth factor 1	Homo sapiens	52-57	
2278223-0	1990	Insulin-like growth factor-I in prednisolone-treated children.	Prednisolone	32-44	insulin like growth factor 1	Homo sapiens	0-28	
2278223-4	1990	A significant increase in plasma IGF-I concentrations was noted during long-term (more than 10 days) prednisolone therapy (P less than 0.001), but not found shortly after prednisolone administration.	Prednisolone	101-113	insulin like growth factor 1	Homo sapiens	33-38	
28945869-7	2017	Results: Prednisolone increased IGF-I concentrations and bioactive IGF in serum (P <= 0.001) but not in SBF, which, compared with serum, contained less bioactive IGF (~28%) after prednisolone (P < 0.05).	Prednisolone	9-21	insulin like growth factor 1	Homo sapiens	32-37	
31159802-2	2019	Anti-inflammatory treatment with prednisolone or infliximab ameliorates symptoms and increases circulating IGF-I, but prednisolone induces catabolism, whereas infliximab may promote protein synthesis.	Prednisolone	33-45	insulin like growth factor 1	Homo sapiens	107-112	
31159802-11	2019	RESULTS: Following seven days of prednisolone treatment, total and bioactive IGF-I were increased (p < 0.001 and p < 0.05, respectively).	Prednisolone	33-45	insulin like growth factor 1	Homo sapiens	77-82	
31159802-15	2019	CONCLUSION: IGF-I and IGFBP-4 concentrations were markedly altered in patients with IBD and near-normalized with disease remission following treatment with prednisolone or infliximab.	Prednisolone	156-168	insulin like growth factor 1	Homo sapiens	12-17	
28945869-12	2017	Finally, prednisolone suppressed post-IGF-IR signaling pathways at the level of insulin receptor substrate 1 (P < 0.05) but did not change skeletal muscle IGF-IR, IGF-I, or STC2 messenger RNA.	Prednisolone	9-21	insulin like growth factor 1	Homo sapiens	38-43	
28945869-13	2017	Conclusion: Prednisolone increased IGF-I concentrations and IGF bioactivity in serum but not in tissue fluid.	Prednisolone	12-24	insulin like growth factor 1	Homo sapiens	35-40	
28688245-6	2017	RESULTS: Evening prednisolone suppressed 24hour GH secretion (P=0.016), overnight GH secretion (P=0.023) and IGF-I (P=0.024) when compared to morning prednisolone, but not when compared to run-in.	Prednisolone	17-29	insulin like growth factor 1	Homo sapiens	109-114